CN1488400A - Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof - Google Patents
Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof Download PDFInfo
- Publication number
- CN1488400A CN1488400A CNA031422993A CN03142299A CN1488400A CN 1488400 A CN1488400 A CN 1488400A CN A031422993 A CNA031422993 A CN A031422993A CN 03142299 A CN03142299 A CN 03142299A CN 1488400 A CN1488400 A CN 1488400A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lysozyme
- endometritis
- biological preparation
- weight percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides a preparation to prevent and cure endometritis of milch cow. It comprises soluble staphylococcus enzyme, Lysozyme, bacteriostatic peptide and carrier. It has strong sterilizing effect, wide sterilizing spectrum and strong stability, easy to accept by human body. The curative effect is quick and it is convenient to use. It can be applied to prevent and cure not only endometritis of milch cow, but also bacterial infectious diseases of milch cow or other animals such as acute and chronic mastitis, colpitis, foot&mouth disease, stomatitis, etc.
Description
Technical field
The present invention relates to a kind of biotype biocide preparation, specifically, relate to a kind of biological preparation of cow endometritis and preparation method thereof that is used to prevent and treat.
Background technology
Endometritis is a genital organ disease common in the cattle-raising, is the one of the main reasons that causes cow infertile.Seriously influence breeding and the economic benefit of cattle.Intrusion antibacterials such as the sterilization when being artificial insemination, childbirth or practise midwifery of its main diseases is not tight, and postpartum care is improper cause infection, this epivaginitis, the prolapsus uteri, placenta retention and brucellosis etc., but secondary endometritis all.Its cardinal symptom has: when acute general generation and post-abortion or generation placenta retention, and fervescence, loss of appetite, spirit is depressed.When serious, hogback is exerted duty, often makes to urinate shape, and chronic by acute secondary, the estrus cycle is undesired.
The cow endometritis sickness rate is generally more than 30%, and it is big as seen to suffer from the cattle ratio, and the hard to settle cattle is more.Mostly being antibacterial, pathogenic bacteria, fungus, mycoplasma mixed infection in its main morbid substance causes.Wherein main antibacterial has that streptococcus accounts for 48.89%, colibacillus: 26.7%, and secondly staphylococcus 13.3% is spiral shell shape bacillus, corynebacterium and other antibacterial.
At present both at home and abroad to the treatment of cow endometritis still based on antibiotic, but there are many unfavorable factors in antibiotic therapy.Make antibacterial produce drug resistance easily as (1); (2) the single medicine antimicrobial spectrum is wideless; (3) cause antibiotic remains easily; (4) other side effect." anti-milk is arranged " and mainly use penicillin, streptomycin, gentamycin, chloromycetin, neomycin etc. from using in the cow feed additive in antibiotic or the treatment of diseases processes such as the clinical type of treatment milch cow, recessive type mastitis and cow endometritis, it is extremely serious that these milk that used antibiotic milch cow to extrude are sneaked into the consequence that causes in the edible milk.FAO (Food and Agriculture Organization of the United Nation) (FAO) and The World Health Organization's suggestion, the milk of extruding in (preferably drug withdrawal 5-7 days) at least 3 days after milch cow is accepted the antibiotic therapy drug withdrawal is not directly as edible milk material.Be present in the milk or meat in residue, can cause people's anaphylaxis, also can make Crinis Carbonisatus rawhide rash etc.Antibiotic residual in milk as the important social public hazards, forbidden listing already in American-European countries, and implements the management method that milk that residual period extrudes all abandons.As the food and bureau of drug (F.D.A) regulation of the U.S., the antibiotic content in every ml milk must not surpass 0.006 iu, uses antibiotic milk discarded 96 hours planted agents." food hygiene law " of various countries' promulgation at present all stipulated, uses the milk of antibiotic therapy mastitis, must not be as food selling in 5 days.Developed country also to the selective examination in every month of each product fresh milk once, penalizes as finding the residual antibiotic person, stipulates simultaneously in a single day the poultry master that must accuse when the veterinary uses antibiotic must not sell the edible time limit with fresh milk, is to blame otherwise find the veterinary.
The traditional Chinese medical science, traditional Chinese veterinary medicine are used the disease that natural drug (Chinese herbal medicine) is treated the human and animal, now are described as natural medical science.As CN1302634A (medicine of treatment inflammation of uterus), but because the drug action of Chinese medicine is slow, so that state of an illness protracted course of disease, or outbreak repeatedly, thereby clinical result of use and bad.
US 4692452 (Method for treatment of endometritis in mammalianfemales), reported the endometritis for the treatment of animal (especially milch cow) with chemicals, but chemicals often has zest to endometrium, can cause the endometrium fibrosis, so that the formation cicatrix, be unfavorable for milch cow further breeding become pregnant.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of biological sterilization preparations that is used for cow endometritis and preparation method thereof, undesirable to overcome the bactericidal effect that prior art exists, antibacterial easily produces drug resistance, easily produce drug accumulation and residual, the state of an illness is easily shown effect repeatedly and is influenced the follow-up defective of becoming pregnant and breeding.
The invention provides a kind of biological preparation, said preparation comprises staphylococcus lysozyme (Lysostaphin), lysozyme (Lysozyne), bacteriostatic peptide (Antimicrobial Peptide) and medically acceptable carrier.
Staphylococcus lysozyme wherein is one or more in agriotype, reorganization generation, mutant or any reorganization that contains the glycine cross-bond that keeps the staphylococcus whole cell peptidoglycan or the relevant enzyme; Staphylococcus lysozyme derives from Staphylococus Simulans and secretes protein product outside born of the same parents, and the nucleic acid of its gene is formed 1486 nucleotide; Molecular weight of albumen 6803Da, form by 244 aminoacid, WO0129201 (Expression of recombinant muture lysostaphin) and DE4425645 (New lysostaphin gene with deletion in pro-segment repeatregion) have reported the staphylococcus lysozyme of reorganization and the staphylococcus lysozyme of sudden change respectively, but its bactericidal activity remains unchanged.The sterilization mechanism of staphylococcus lysozyme is by the glycine key in the narrow spectrum cut-out muramyl peptide polysaccharide, reaches the effect of quick kill pathogenic organisms.Used staphylococcus lysozyme is that Gaoke Bio-Engineering Co Ltd, Shanghai produces by gene recombination technology, and excretory by the bacillus subtilis amplification, the specific activity scope of its enzyme is 300-1200 unit/milligram.
Lysozyme is one or more in bacterial cell wall lyase, yeast cell wall lyase, the mycete cell wall lyase; Used lysozyme is the active component that extracts from Ovum Gallus domesticus album, is the crude drug that meets the Chinese Pharmacopoeia standard, and lysozyme is by acting on β-1,4 glycosidic bond in the cell wall or β-1,3 glucosan and killing bacteria.
Bacteriostatic peptide is the natural bacteriostatic peptide that extracts from animals and plants or microorganism or the polypeptide with bactericidal action by mechanochemical method or technique for gene engineering production, used bacteriostatic peptide is that Shanghai Hi-Tech United Biotechnology R ﹠ D Ltd adopts the solid state chemistry synthetic method, with the synthetic GK-1 polypeptide of Peptide synthesizer, the particulars of the bacteriostatic peptide of being addressed can be referring to CN1398897A.It is little that micromolecule polypeptide has a molecular weight, and the sterilization permeability is strong, the characteristics that toxic and side effects is little, and the sterilization mechanism of bacteriostatic peptide is to play a role by boring a hole on the cell membrane of antibacterial.
Wherein the weight percent content of staphylococcus lysozyme is 0.001-10%;
The weight percent content of lysozyme is 0.01-30%;
The weight percent content of bacteriostatic peptide is 0.0001-10%.
Preferred weight percent content is that staphylococcus lysozyme is 0.001-5%, and lysozyme is 0.1-10%, and bacteriostatic peptide is 0.01-1%.
Comprise also in this complex preparation that weight percent content is that protein stabilizing agent and the weight percent content of 0.2-60% is the penetration enhancer of 0.5-50%.
Protein stabilizing agent is medicinal macromolecular compounds such as polyethylene glycol substances or chitosan, chitin, N-acetyl-D-amino, can wrap up protein or polypeptide, avoids the destruction of other materials, thereby strengthens the stability of protein or polypeptide.
Penetration enhancer comprises one or more in ethanol, saturated or unsaturated fatty acid and ester thereof, surfactant, the chelating agen, not only can strengthen preparation to endometrial infiltration, strengthen effective performance of its bactericidal action, and can strengthen the stability of enzyme.
Wherein said and polyethylene glycol substances comprise it being in PEG400, cetomacrogol 1000, polyethylene glycol 1500, Macrogol 4000 or the polyethylene glycol 6000 one or more.
Saturated or unsaturated fatty acid and ester thereof comprise one or more in lauric acid, myristic acid, the laurate.
Surfactant comprises one or more in tween (Tween), cholate, the span (Span).
Chelating agen such as ethylenediaminetetraacetic acid (EDTA), disodiumedetate, sodium iron ethylenediaminetetraacetate etc.
Said preparation can be made water preparation, powder, suppository, membrane, gel, ointment or ointment.According to the needs of different dosage form, need in the preparation to add different substrate or carrier, the degree of its mesostroma or carrier all is medically common dosage.
The substrate that suppository is commonly used is one or more of semi-synthetic fatty acid glyceride, oleum theobromatis, Myrj 45, hydrogenated vegetable oil, glycerin gelatine, Polyethylene Glycol apoplexy due to endogenous wind.
Need to add one or more filmogens in the membrane, filmogen can be natural or synthetic macromolecular compound, as starch, dextrin, cellulose, gelatin, agar, chitin, cellulose derivative, polyethylene amine, polyvinyl alcohol, hyprolose etc., also can add plasticizer such as glycerol, sorbitol etc.
Used substrate can be one or more in glycerin gelatine, starch, cellulose derivative, the Polyethylene Glycol in the gel.
The substrate that adds in the ointment can be one or more in hydroxyl class, oils or the lipoid, wherein hydroxyl class such as vaseline, hard paraffin, liquid paraffin, silicone etc.; Oils such as Oleum Arachidis hypogaeae semen, Oleum Gossypii semen, hydrogenated vegetable wet goods; Lipoid such as lanoline, Cera Flava, cholesterol etc.
The emulsifying agent that adds in the ointment can be one or more in naturally occurring emulsifying agent or the synthetic emulsifier, naturally occurring emulsifying agent wherein such as arabic gum, animal glue, alginate, lecithin etc.; Synthetic emulsifier such as cellulose derivative, tristerin, sucrose-fatty esters, tween (Tween) etc.
The invention also discloses the preparation method of said preparation,, will take different preparation methoies, but overall preparation method is exactly with several compositions according to different dosage forms, according to its ratio, mix homogeneously, promptly available after to be formed.Water preparation can directly be filled into intrauterine, and powder preparation directly is filled into intrauterine after diluting with distilled water or pure water, and suppository etc. are then directly filled in intrauterine from vagina.
Said preparation has following characteristics:
1. bactericidal effect is strong, and fungicidal spectrum is wide.Said preparation is to gram positive bacteria and gram negative bacteria and part is viral and fungus is all effective, especially staphylococcus aureus, escherichia coli, streptococcus (streptococcus agalactiae, streptococcus dysgalactiae, streptococcus uberis), Cray Bai Shi bacillus, staphylococcus epidermidis, bacillus pyocyaneus, Candida albicans etc., the experiment in vitro effect can reach 99.9% sterilizing rate in 5 minutes, if act on 10 minutes even 20 minutes, can make sterilizing rate reach 100%, above-mentioned antibacterial all is antibacterials common when suckling cattle uterus generation infection.(seeing Table 1～4).
2. several biological preparation are composite, and stability is strong, and 54 ℃ to deposit 2 all bactericidal activities constant.The present invention carries out enzyme and micromolecule bacteriostatic peptide composite first, not only kept bactericidal activity separately, and because can interact between the various compositions, experimental results show that, after composite not only bactericidal activity strengthen (10-40 doubly to the simple superposition of three's bactericidal effect) greatly than three's bactericidal activity separately, and the stability of enzyme is strengthened, deposit 2 week backs (being equivalent to room temperature preserved 2 years) for 54 ℃, said preparation remains unchanged to the bactericidal activity of staphylococcus aureus, still, act on 20 minutes and can reach 100% more than 99.9%.(seeing Table 5).
3. the present invention is pure biological preparation and medically acceptable carrier, has overcome traditional chemical class preparation uterine mucosa is had zest, and antibacterial is easy to generate chemical sproof shortcoming.Easily accepted by body, and without any toxic and side effects.The acute and chronic toxicological test result who carries out through sterilization section of Shanghai Disease Prevention and Control Centre shows that said preparation is nontoxic non-stimulated product.
4. among the present invention enzyme and bacteriostatic peptide are used for first the prevention and the treatment of cow endometritis, the influence that can avoid traditional antibiotic therapy cow endometritis that milch cow itself and milk are caused, avoid " anti-milk being arranged " to the human body health affected, and can save cost, have vast market prospect and application prospect.
5. this preparation adopts the mode of local application, and it is fast that systemic treatment commonly used has therapeutical effect, the characteristics that toxic and side effects is little, and easy to use, be easy to be accepted by veterinary and milch cow.
6. preparation of the present invention not only can be used for preventing and treating the endometritis of milch cow, can also be used to prevent and treat the bacterial infection disease such as acute and chronic mastitis, vaginitis, foot and mouth disease, stomatitis, skin ulcer, skin injury, systemic infection, inflammation of external auditory canal of milch cow or other animals.
Attached: one. the sterilization experiment data:
The killing effect of table 1 pair staphylococcus aureus
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stock solution 99.83 99.97 100 100
(99.82-99.84)?(99.96-99.98)
50 99.25 99.83 99.92 99.99
(99.19-99.31)?(99.82-99.84) (99.90-99.94) (99.99-100)
25 98.05 99.34 99.70 99.96
(97.80-98.30)?(99.31-99.38) (99.68-99.71) (99.95-99.98)
Annotate: average bacterium number of positive controls and scope are 7.25 * 10
5Cfu/ sheet (7.15-7.35 * 10
5The cfu/ sheet)
Negative control group: nertralizer, PBS, culture medium do not have bacterial growth.
Table 2 pair colibacillary killing effect
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stock solution 99.73 99.95 99.99 100
(99.70-99.77) (99.95-99.96) (99.99-100)
50 99.28 99.67 99.89 99.94
(99.23-99.31) (99.64-99.70) (99.88-99.90) (99.94-99.95)
25 97.02 98.98 99.4?1 99.83
(96.83-97.21) (98.87-99.08) (99.36-99.48) (99.82-99.84)
Annotate: average bacterium number of positive controls and scope are 6.00 * 10
5Cfu/ sheet (5.80-6.20 * 10
5The cfu/ sheet)
Negative control group: nertralizer, PBS, culture medium do not have bacterial growth.
Table 3 pair streptococcic killing effect
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stock solution 99.88 99.96 100 100
(99.87-99.89) (99.96-99.96)
50 99.53 99.89 99.99 100
(99.49-99.57) (99.88-99.90) (99.99-99.99)
25 98.92 99.59 99.79 99.98
(98.84-99.01) (99.56-99.63) (99.75-99.81) (99.98-99.98)
Annotate: average bacterium number of positive controls and scope are 7.00 * 10
5Cfu/ sheet (6.80-7.20 * 10
5The cfu/ sheet)
Negative control group: nertralizer, PBS, culture medium do not have bacterial growth.
The killing effect of table 4 pair Cray Bai Shi bacillus
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stock solution 99.87 99.95 99.99 100
(99.86-99.91) (99.94-99.97) (99.99-100)
75 97.95 99.88 99.97 99.99
(97.85-98.08) (99.86-99.95) (99.96-99.99) (99.99-100)
50 92.05 99.03 99.89 99.99
(91.94-92.84) (98.98-99.07) (99.86-99.93) (99.99-99.99)
Annotate: average bacterium number of positive controls and scope are 1.86 * 10
6Cfu/ sheet (1.82-1.89 * 10
6The cfu/ sheet)
Negative control group: nertralizer, PBS, culture medium do not have bacterial growth.Two. stability test
Table 5 is deposited 2 all backs to the staphylococcus aureus killing effect for 54 ℃
The average clump count effect of storage temperature matched group different time (min) average kill ratio and scope (%)
And time and scope
(℃, d) (cfu/ sheet) 25 10 20
54 14 5.80×10
5 99.69 99.93 99.98 100
(5.70-5.90×10
5)?(99.69-99.70) (99.93-99.94) (99.97-99.99)
Annotate: negative control group does not have bacterial growth.Three. toxicological experiment (detection unit: sterilization section of Shanghai Disease Prevention and Control Centre)
1, acute oral toxicity test:
Mice LD
50＞5000mg/kg
The nontoxic level in true border
2, skin irritation test: belong to nonirritant.
3, vaginal mucomembranous irritant test: belong to nonirritant.
4, eye irritant test: belong to nonirritant.
5, cumulative toxicity test: cumulative coefficient K＞5, the property accumulated a little less than the genus.
6, micronucleus test: do not have the micronucleus effect that causes.Four. clinical experiment
In Shanghai, more than 20 regional clinical trial results such as Tianjin, Beijing, Guangzhou, Shenyang, Wuhan show: puerperal, the milch cow continuous application was 2-3 time, and clinical effective rate reaches about 90%.
The specific embodiment
Embodiment 1
Staphylococcus lysozyme 0.01 gram
Lysozyme 2 grams
GK-1 bacteriostatic peptide 0.5 gram
Chitin 2 grams
EDTA 20 grams
Above-mentioned substance is diluted to 100 milliliters with distilled water or pure water, can directly be filled into intrauterine water formulation.
Embodiment 2
Staphylococcus lysozyme 0.01 gram
Lysozyme 1 gram
GK-1 bacteriostatic peptide 0.05 gram
Chlorhexidine acetate 0.03 gram
Glyceryl monostearate 5 grams
Chitosan 1 gram
Above-mentioned substance is mixed, and sub-dose packaging is powder preparation.During use, reuse distilled water or pure water are diluted to the 100-200 milliliter with it, can directly be filled into intrauterine water formulation.
Embodiment 3
Staphylococcus lysozyme 10 grams
Lysozyme 0.05 gram
GK-1 bacteriostatic peptide 0.2 gram
Glycerol 1 gram
Tween 2 grams
Cetomacrogol 1000 20 grams
Myrj 45 50 grams
Water is an amount of
With the above-mentioned substance mixing, can make suppository.
Claims (8)
1. a biological preparation that is used to prevent and treat cow endometritis is characterized in that said preparation comprises staphylococcus lysozyme, lysozyme, bacteriostatic peptide and medically acceptable carrier.
2. biological preparation according to claim 1 is characterized in that the weight percent content of staphylococcus lysozyme, lysozyme and bacteriostatic peptide is respectively 0.001-10%, 0.01-30% and 0.0001-10%.
3. biological preparation according to claim 2 is characterized in that the weight percent content of staphylococcus lysozyme, lysozyme and bacteriostatic peptide is respectively 0.001-5%, 0.1-10% and 0.01-1%.
4. biological preparation according to claim 1, it is characterized in that said preparation comprises that weight percent content is respectively the staphylococcus lysozyme of 0.001-5%, 0.1-10%, 0.01-1%, 0.2-60% and 0.5-50%, lysozyme, bacteriostatic peptide, protein stabilizing agent and penetration enhancer, and medically acceptable carrier.
5. biological preparation according to claim 4 is characterized in that described protein stabilizing agent is one or more in polyethylene glycol substances, chitosan, chitin or the N-acetyl-D-amino; Described penetration enhancer is one or more in ethanol, saturated or unsaturated fatty acid and ester thereof, surfactant, the chelating agen.
6. according to each described biological preparation of claim 1-5, the dosage form that it is characterized in that said preparation is water preparation, powder, suppository, membrane, gel, ointment or ointment.
7. according to each described biological preparation of claim 1-5, the dosage form that it is characterized in that said preparation is powder or suppository.
8. according to the preparation method of each described biological preparation of claim 1-7, it is characterized in that each component being prepared into required dosage form and getting final product according to its weight percent content mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031422993A CN100335126C (en) | 2003-08-18 | 2003-08-18 | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031422993A CN100335126C (en) | 2003-08-18 | 2003-08-18 | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488400A true CN1488400A (en) | 2004-04-14 |
| CN100335126C CN100335126C (en) | 2007-09-05 |
Family
ID=34155692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031422993A Expired - Lifetime CN100335126C (en) | 2003-08-18 | 2003-08-18 | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100335126C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100388949C (en) * | 2005-08-09 | 2008-05-21 | 上海高科联合生物技术研发有限公司 | Lysostaphin freeze dried powder used for preventing and treating cattle edometritis |
| CN1911442B (en) * | 2005-08-09 | 2010-06-30 | 上海高科联合生物技术研发有限公司 | Lysostaphin freeze dried powder used for preventing and treating trauma surface infestation |
| CN101766813A (en) * | 2008-12-30 | 2010-07-07 | 上海高科联合生物技术研发有限公司 | Suppository for treating mammalian endometritis and preparation method thereof |
| CN102552888A (en) * | 2010-12-10 | 2012-07-11 | 上海高科联合生物技术研发有限公司 | Suppository for treating mammal endometritis |
| CN103784948A (en) * | 2012-11-05 | 2014-05-14 | 上海高科联合生物技术研发有限公司 | Effervescent suppository for treating mammal vaginitis |
| CN104524559A (en) * | 2014-12-16 | 2015-04-22 | 杨陈 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
| CN104524558A (en) * | 2014-12-11 | 2015-04-22 | 杨陈 | Enzyme compounded preparation and preparation method thereof |
| CN104606672A (en) * | 2014-12-11 | 2015-05-13 | 杨陈 | Staphylococcus-dissolving composite enzyme sterilization spraying agent and preparation method thereof |
| CN106668850A (en) * | 2015-11-05 | 2017-05-17 | 惠众国际医疗器械（北京）有限公司 | Natural bactericides/antibacterial agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042826A1 (en) * | 1998-02-06 | 1999-08-26 | University Of Pittsburgh | Screening method for reproductive tract inflammation and preeclampsia using neutrophil defensins |
| CN1125592C (en) * | 2000-06-08 | 2003-10-29 | 上海高科生物工程有限公司 | Compound lysostaphin enzyme disinfectant |
| CN1269837C (en) * | 2002-09-02 | 2006-08-16 | 上海高科联合生物技术研发有限公司 | Serial synthetic antibacterial peptide |
-
2003
- 2003-08-18 CN CNB031422993A patent/CN100335126C/en not_active Expired - Lifetime
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100388949C (en) * | 2005-08-09 | 2008-05-21 | 上海高科联合生物技术研发有限公司 | Lysostaphin freeze dried powder used for preventing and treating cattle edometritis |
| CN1911442B (en) * | 2005-08-09 | 2010-06-30 | 上海高科联合生物技术研发有限公司 | Lysostaphin freeze dried powder used for preventing and treating trauma surface infestation |
| CN101766813A (en) * | 2008-12-30 | 2010-07-07 | 上海高科联合生物技术研发有限公司 | Suppository for treating mammalian endometritis and preparation method thereof |
| CN102552888A (en) * | 2010-12-10 | 2012-07-11 | 上海高科联合生物技术研发有限公司 | Suppository for treating mammal endometritis |
| CN103784948A (en) * | 2012-11-05 | 2014-05-14 | 上海高科联合生物技术研发有限公司 | Effervescent suppository for treating mammal vaginitis |
| CN104524558A (en) * | 2014-12-11 | 2015-04-22 | 杨陈 | Enzyme compounded preparation and preparation method thereof |
| CN104606672A (en) * | 2014-12-11 | 2015-05-13 | 杨陈 | Staphylococcus-dissolving composite enzyme sterilization spraying agent and preparation method thereof |
| CN104524559A (en) * | 2014-12-16 | 2015-04-22 | 杨陈 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
| CN106668850A (en) * | 2015-11-05 | 2017-05-17 | 惠众国际医疗器械（北京）有限公司 | Natural bactericides/antibacterial agents |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100335126C (en) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102655754B (en) | Antimycotic mixture comprising fungal organism pythium oligandrum | |
| AU2005257722A1 (en) | Composition comprising lactic acid and lactoferrin | |
| CN100335126C (en) | Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof | |
| US20220323640A1 (en) | Liquid dressing compositions and their uses | |
| CN1316965C (en) | Transparent disappearing external administration carrier | |
| CN1209972C (en) | Sterilization formulation and wet tissue, preparation method and use | |
| CN1367018A (en) | Compound preparation of staphylococcolysis enzyme and its preparation method and application | |
| CN101288769A (en) | Bactericide for pet and preparation method thereof | |
| CN101642467B (en) | Long-acting disinfection paste | |
| CN113273646A (en) | Powder for sow parturition and inoculation as well as preparation method and application thereof | |
| CN114652767B (en) | Dairy cow nipple medicated bath agent and preparation method thereof | |
| CN1765369A (en) | Nano silver gel and its use | |
| CN1157230C (en) | Bactericidal gauze with lysostaphin complex enzyme | |
| CN1513530A (en) | Chinese medicine for treating ashen nail and its preparation method | |
| JP5716214B2 (en) | Bread seed-based mixture | |
| RU2598338C1 (en) | Method for the treatment of serous mastitis in cattle | |
| CN1857274A (en) | Medicine composition for treating valval and/or vaginal infection | |
| CN100431419C (en) | Biological agent for foot disinfection | |
| JP2023518928A (en) | Compositions for interfering with biofilm formation and for treating biofilm-related disorders | |
| CN100360016C (en) | Foot disinfectant | |
| CN112076252A (en) | Ozone antibacterial gel and preparation method thereof | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| CN1911441A (en) | Lysostaphin freeze dried powder used for preventing and treating cattle edometritis | |
| CN1164278C (en) | Biological preparation for curing burn and its preparation method | |
| CN110960541B (en) | Pharmaceutical composition for penaeus vannamei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KUNSHAN BOQING BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GAOKE BIO-ENGINEERING CO LTD, SHANGHAI Effective date: 20100513 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201206 NO.501, JINGANG ROAD, PUDONG NEW DISTRICT, SHANGHAI TO: 215300 HUANQING ROAD (SOUTH), YUSHAN TOWN (NORTH), KUNSHAN CITY, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100513 Address after: 215300, Kunshan, Yushan Town, Jiangsu City, South Road, North Ring Road Patentee after: KUNSHAN BIOGREEN TECHNOLOGY Co.,Ltd. Address before: 201206 No. 501 Jingang Road, Shanghai, Pudong New Area Patentee before: Shanghai Hi-tech Bioengineering Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070905 |